REGENESIS (CA): A Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients - Related Studies

REGENESIS (CA): A Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients

This study is ongoing, but not recruiting participants.

Study NCT00663416. Last updated on September 18, 2008. Information provided by Stem Cell Therapeutics Corp.

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Stroke

2	More general conditions related to this trial
		Brain Diseases
		Cardiovascular Diseases
		Central Nervous System Diseases
		Cerebrovascular Disorders
		Nervous System Diseases
		Vascular Diseases

3	Interventions listed in this trial
		NTx™-265: rhCG, then rEPO
		Saline placebo

4	Additional drug interventions recognized in this trial
		Chorionic Gonadotropin
		Epoetin Alfa

5	More general drug interventions related to this trial
		Hematinics
		Hematologic Agents
		Pharmacologic Actions
		Physiological Effects of Drugs
		Reproductive Control Agents
		Therapeutic Uses

6	Sponsors listed in this trial
		Stem Cell Therapeutics Corp.